An analysis of the Food and Drug Administration’s Adverse Event Reporting System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users of Reglan or its generic version, metoclopramide. Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements of the extremities, including lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. These symptoms are rarely reversible and there is no known treatment.